Oregon Public Employees Retirement Fund Reduces Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Oregon Public Employees Retirement Fund reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 2.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 33,506 shares of the medical device company’s stock after selling 780 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in DexCom were worth $2,606,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in DXCM. Jennison Associates LLC lifted its position in shares of DexCom by 1,683.2% during the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after purchasing an additional 6,544,102 shares in the last quarter. Congress Asset Management Co. boosted its position in DexCom by 5,456.9% in the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock valued at $105,529,000 after buying an additional 1,332,522 shares during the last quarter. Fisher Funds Management LTD purchased a new position in DexCom in the 4th quarter valued at about $96,507,000. Westfield Capital Management Co. LP boosted its position in DexCom by 44.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after buying an additional 876,739 shares during the last quarter. Finally, Two Sigma Advisers LP grew its stake in DexCom by 182.7% during the 3rd quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock valued at $76,659,000 after purchasing an additional 739,000 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,083 shares of company stock valued at $3,309,794. Company insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on DXCM shares. Wells Fargo & Company raised their price objective on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Morgan Stanley lifted their price target on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and upped their target price for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Finally, Canaccord Genuity Group increased their target price on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $99.06.

DexCom Trading Down 2.3 %

DexCom stock opened at $87.81 on Friday. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The firm has a market capitalization of $34.31 billion, a price-to-earnings ratio of 61.41, a PEG ratio of 2.30 and a beta of 1.14. The firm has a 50-day moving average price of $84.53 and a two-hundred day moving average price of $76.55. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Sell-side analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.